The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Alzamend Neuro Inc. (ALZN) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.003, or -0.51%, to $0.59. The Alzamend Neuro Inc. has recorded 697 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial.
Alzamend Neuro Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $0.59 and fluctuated between $0.6119 as its day high and $0.5700 as its day low. The current market capitalization of Alzamend Neuro Inc. is $54.80M. A total of 0.31 million shares were traded on the day, compared to an average of 365.59K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ALZN has seen 5 BUY and 0 SELL insider trades, representing the acquisition of 16,000 and the disposition of 0 shares. Over the last 12 months, there were 28 BUYs and 3 SELLs from insiders. Insiders purchased 3,180,600 shares during that period but sold 102,016.
In the most recent transaction, AULT MILTON C III bought 3,100 shares of ALZN for 0.56 per share on Dec 28. After the transaction, the 10% Owner now owns 11,050,001 company shares. In a previous transaction on Dec 27, AULT MILTON C III bought 900 shares at 0.59 per share. ALZN shares that 10% Owner owns now total 11,046,901.
Among the insiders who bought shares, AULT MILTON C III acquired of 5,000 shares on Dec 21 at a per-share price of $0.81. This resulted in the 10% Owner holding 11,046,001 shares of ALZN after the transaction. In another insider transaction, AULT MILTON C III bought 23,000 shares at $0.82 per share on Dec 19. Company shares held by the 10% Owner now total 11,041,001.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ALZN in the last 3 months, the mean price target is $7.00 with high estimates of $7.00 and low estimates of $7.00. In terms of 52-week highs and lows, ALZN has a high of $1.98 and a low of $0.49.
As of this writing, ALZN has an earnings estimate of -$0.05 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.04 per share and a lower estimate of -$0.06. The company reported an EPS of -$0.04 in the last quarter, which was -33.30% lower than expectations of -$0.03.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALZN is Buy with a score of 0.00. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.